1 | curves | 3,031 |
2 | titers | 1,490 |
3 | titer | 787 |
4 | plots | 683 |
5 | plot | 574 |
6 | titres | 472 |
7 | titre | 227 |
8 | diagrams | 124 |
9 | ≥1:8 | 24 |
10 | draconis | 18 |
11 | ctfs | 14 |
12 | pratensis | 11 |
13 | drls | 10 |
14 | seroprevalences | 9 |
15 | concentrations/titers | 7 |
16 | stripassay | 6 |
17 | incidence/prevalence | 5 |
18 | ≥10miu/ml | 5 |
19 | -concentrations | 4 |
20 | eia-pi | 4 |
21 | syndrome-positive | 4 |
22 | ammeline | 3 |
23 | coeff | 3 |
24 | equivalents/ml | 3 |
25 | splitters | 3 |
26 | ≥0.35μg/ml | 3 |
27 | ≥100miu/ml | 3 |
28 | 150°/s | 2 |
29 | 9508 | 2 |
30 | anti-gal3 | 2 |
31 | cuo4 | 2 |
32 | dyslypidemia | 2 |
33 | methology | 2 |
34 | relationship.the | 2 |
35 | rt17-b1 | 2 |
36 | syndrome-negative | 2 |
37 | watched/night | 2 |
38 | 1077bf | 1 |
39 | 14g2a | 1 |
40 | 183b2 | 1 |
41 | 19044 | 1 |
42 | 2h6 | 1 |
43 | 2h7 | 1 |
44 | 4b7 | 1 |
45 | 90/cpn91 | 1 |
46 | a45b/b3 | 1 |
47 | al-adha | 1 |
48 | analysis-of-variances | 1 |
49 | analysis.mean±standard | 1 |
50 | anovatest | 1 |
51 | anti-sap | 1 |
52 | apo2.7 | 1 |
53 | aqueous-extracts | 1 |
54 | assessments+feedback | 1 |
55 | b-ly1 | 1 |
56 | based-uplc-q-tof-hdms | 1 |
57 | benefit-the | 1 |
58 | besilesomab | 1 |
59 | broadcastings | 1 |
60 | celite-activated | 1 |
61 | circo-like | 1 |
62 | coefficient=1.08 | 1 |
63 | coefficient=6.13 | 1 |
64 | complications/interventions | 1 |
65 | concentrations/titres | 1 |
66 | dako-ebv | 1 |
67 | desulphydrase | 1 |
68 | diagnosis/es | 1 |
69 | direct-infusion | 1 |
70 | do-7 | 1 |
71 | editorialists | 1 |
72 | eigenmaps | 1 |
73 | eo6 | 1 |
74 | experimentum | 1 |
75 | fh-6 | 1 |
76 | glycemia.participants | 1 |
77 | hdl-c-values | 1 |
78 | hmfg-2 | 1 |
79 | jj316 | 1 |
80 | k1-70 | 1 |
81 | maiya | 1 |
82 | medi-563 | 1 |
83 | mesolizumab | 1 |
84 | message/month | 1 |
85 | method-derived | 1 |
86 | model_017 | 1 |
87 | ncl-calp-12a2 | 1 |
88 | nd-1 | 1 |
89 | nitrogen/ml | 1 |
90 | nm57 | 1 |
91 | ns19-9 | 1 |
92 | pab1801 | 1 |
93 | parv-19 | 1 |
94 | path-lengths | 1 |
95 | phenomenon-which | 1 |
96 | processing/analysis | 1 |
97 | pyrokinins | 1 |
98 | rm-ancova | 1 |
99 | sample-to-positive | 1 |
100 | stopcocks | 1 |
101 | tears® | 1 |
102 | teprotumumab | 1 |
103 | testology | 1 |
104 | time-to-healing | 1 |
105 | titer≥40 | 1 |
106 | titre≥1:80 | 1 |
107 | ts-106 | 1 |
108 | turbo-flash | 1 |
109 | vt7 | 1 |
110 | ≤-2·0 | 1 |
1 | -concentrations | 4 |
2 | 1077bf | 1 |
3 | 14g2a | 1 |
4 | 150°/s | 2 |
5 | 183b2 | 1 |
6 | 19044 | 1 |
7 | 2h6 | 1 |
8 | 2h7 | 1 |
9 | 4b7 | 1 |
10 | 90/cpn91 | 1 |
11 | 9508 | 2 |
12 | a45b/b3 | 1 |
13 | al-adha | 1 |
14 | ammeline | 3 |
15 | analysis-of-variances | 1 |
16 | analysis.mean±standard | 1 |
17 | anovatest | 1 |
18 | anti-gal3 | 2 |
19 | anti-sap | 1 |
20 | apo2.7 | 1 |
21 | aqueous-extracts | 1 |
22 | assessments+feedback | 1 |
23 | b-ly1 | 1 |
24 | based-uplc-q-tof-hdms | 1 |
25 | benefit-the | 1 |
26 | besilesomab | 1 |
27 | broadcastings | 1 |
28 | celite-activated | 1 |
29 | circo-like | 1 |
30 | coeff | 3 |
31 | coefficient=1.08 | 1 |
32 | coefficient=6.13 | 1 |
33 | complications/interventions | 1 |
34 | concentrations/titers | 7 |
35 | concentrations/titres | 1 |
36 | ctfs | 14 |
37 | cuo4 | 2 |
38 | curves | 3,031 |
39 | dako-ebv | 1 |
40 | desulphydrase | 1 |
41 | diagnosis/es | 1 |
42 | diagrams | 124 |
43 | direct-infusion | 1 |
44 | do-7 | 1 |
45 | draconis | 18 |
46 | drls | 10 |
47 | dyslypidemia | 2 |
48 | editorialists | 1 |
49 | eia-pi | 4 |
50 | eigenmaps | 1 |
51 | eo6 | 1 |
52 | equivalents/ml | 3 |
53 | experimentum | 1 |
54 | fh-6 | 1 |
55 | glycemia.participants | 1 |
56 | hdl-c-values | 1 |
57 | hmfg-2 | 1 |
58 | incidence/prevalence | 5 |
59 | jj316 | 1 |
60 | k1-70 | 1 |
61 | maiya | 1 |
62 | medi-563 | 1 |
63 | mesolizumab | 1 |
64 | message/month | 1 |
65 | method-derived | 1 |
66 | methology | 2 |
67 | model_017 | 1 |
68 | ncl-calp-12a2 | 1 |
69 | nd-1 | 1 |
70 | nitrogen/ml | 1 |
71 | nm57 | 1 |
72 | ns19-9 | 1 |
73 | pab1801 | 1 |
74 | parv-19 | 1 |
75 | path-lengths | 1 |
76 | phenomenon-which | 1 |
77 | plot | 574 |
78 | plots | 683 |
79 | pratensis | 11 |
80 | processing/analysis | 1 |
81 | pyrokinins | 1 |
82 | relationship.the | 2 |
83 | rm-ancova | 1 |
84 | rt17-b1 | 2 |
85 | sample-to-positive | 1 |
86 | seroprevalences | 9 |
87 | splitters | 3 |
88 | stopcocks | 1 |
89 | stripassay | 6 |
90 | syndrome-negative | 2 |
91 | syndrome-positive | 4 |
92 | tears® | 1 |
93 | teprotumumab | 1 |
94 | testology | 1 |
95 | time-to-healing | 1 |
96 | titer | 787 |
97 | titers | 1,490 |
98 | titer≥40 | 1 |
99 | titre | 227 |
100 | titres | 472 |
101 | titre≥1:80 | 1 |
102 | ts-106 | 1 |
103 | turbo-flash | 1 |
104 | vt7 | 1 |
105 | watched/night | 2 |
106 | ≤-2·0 | 1 |
107 | ≥0.35μg/ml | 3 |
108 | ≥100miu/ml | 3 |
109 | ≥10miu/ml | 5 |
110 | ≥1:8 | 24 |
1 | titer≥40 | 1 |
2 | k1-70 | 1 |
3 | titre≥1:80 | 1 |
4 | ≤-2·0 | 1 |
5 | nd-1 | 1 |
6 | pab1801 | 1 |
7 | 90/cpn91 | 1 |
8 | rt17-b1 | 2 |
9 | b-ly1 | 1 |
10 | hmfg-2 | 1 |
11 | ncl-calp-12a2 | 1 |
12 | 183b2 | 1 |
13 | coefficient=6.13 | 1 |
14 | medi-563 | 1 |
15 | a45b/b3 | 1 |
16 | anti-gal3 | 2 |
17 | 19044 | 1 |
18 | cuo4 | 2 |
19 | fh-6 | 1 |
20 | ts-106 | 1 |
21 | jj316 | 1 |
22 | 2h6 | 1 |
23 | eo6 | 1 |
24 | do-7 | 1 |
25 | apo2.7 | 1 |
26 | model_017 | 1 |
27 | nm57 | 1 |
28 | 4b7 | 1 |
29 | 2h7 | 1 |
30 | vt7 | 1 |
31 | coefficient=1.08 | 1 |
32 | 9508 | 2 |
33 | ≥1:8 | 24 |
34 | ns19-9 | 1 |
35 | parv-19 | 1 |
36 | 14g2a | 1 |
37 | al-adha | 1 |
38 | dyslypidemia | 2 |
39 | rm-ancova | 1 |
40 | maiya | 1 |
41 | besilesomab | 1 |
42 | teprotumumab | 1 |
43 | mesolizumab | 1 |
44 | celite-activated | 1 |
45 | method-derived | 1 |
46 | analysis.mean±standard | 1 |
47 | incidence/prevalence | 5 |
48 | benefit-the | 1 |
49 | relationship.the | 2 |
50 | circo-like | 1 |
51 | ammeline | 3 |
52 | titre | 227 |
53 | desulphydrase | 1 |
54 | syndrome-negative | 2 |
55 | syndrome-positive | 4 |
56 | sample-to-positive | 1 |
57 | 1077bf | 1 |
58 | coeff | 3 |
59 | time-to-healing | 1 |
60 | phenomenon-which | 1 |
61 | turbo-flash | 1 |
62 | message/month | 1 |
63 | eia-pi | 4 |
64 | assessments+feedback | 1 |
65 | ≥0.35μg/ml | 3 |
66 | nitrogen/ml | 1 |
67 | equivalents/ml | 3 |
68 | ≥100miu/ml | 3 |
69 | ≥10miu/ml | 5 |
70 | experimentum | 1 |
71 | direct-infusion | 1 |
72 | anti-sap | 1 |
73 | titer | 787 |
74 | 150°/s | 2 |
75 | diagnosis/es | 1 |
76 | analysis-of-variances | 1 |
77 | seroprevalences | 9 |
78 | titres | 472 |
79 | concentrations/titres | 1 |
80 | hdl-c-values | 1 |
81 | curves | 3,031 |
82 | ctfs | 14 |
83 | broadcastings | 1 |
84 | path-lengths | 1 |
85 | draconis | 18 |
86 | pratensis | 11 |
87 | processing/analysis | 1 |
88 | stopcocks | 1 |
89 | drls | 10 |
90 | diagrams | 124 |
91 | based-uplc-q-tof-hdms | 1 |
92 | pyrokinins | 1 |
93 | -concentrations | 4 |
94 | complications/interventions | 1 |
95 | eigenmaps | 1 |
96 | titers | 1,490 |
97 | concentrations/titers | 7 |
98 | splitters | 3 |
99 | aqueous-extracts | 1 |
100 | glycemia.participants | 1 |
101 | plots | 683 |
102 | editorialists | 1 |
103 | watched/night | 2 |
104 | plot | 574 |
105 | anovatest | 1 |
106 | dako-ebv | 1 |
107 | stripassay | 6 |
108 | methology | 2 |
109 | testology | 1 |
110 | tears® | 1 |